November 16, 2016 - By Linda Rogers · 0 Comments
Palatin Technologies Inc (NYSEMKT:PTN) institutional sentiment increased to 0.8 in 2016 Q2. Its up 0.13, from 0.67 in 2016Q1. The ratio has improved, as 8 investment professionals increased and started new positions, while 10 sold and decreased stock positions in Palatin Technologies Inc. The investment professionals in our partner’s database now have: 11.27 million shares, down from 14.41 million shares in 2016Q1. Also, the number of investment professionals holding Palatin Technologies Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 6 Increased: 8 New Position: 0.
Palatin Technologies, Inc. is a biopharmaceutical company. The company has a market cap of $41.12 million. The Firm is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. It currently has negative earnings. The Company’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
The stock closed at $0.513 during the last session. It is down 4.08% since April 14, 2016 and is uptrending. It has underperformed by 0.60% the S&P500.
According to Zacks Investment Research, “Palatin Technologies, Inc is a development-stage medical technology company involved in developing and commercializing products and technologies for diagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies.”
Sphera Funds Management Ltd. holds 0.12% of its portfolio in Palatin Technologies, Inc. for 1.02 million shares. Qvt Financial Lp owns 4.04 million shares or 0.09% of their US portfolio. Moreover, Highlander Capital Management Llc has 0.03% invested in the company for 67,500 shares. The New York-based Baker Bros. Advisors Lp has invested 0.01% in the stock. National Asset Management Inc., a New York-based fund reported 140,000 shares.#img1#
Palatin Technologies, Inc., incorporated on November 21, 1986, is a biopharmaceutical company. The Firm is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. The Company’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. The Company’s other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). In addition, it has drug candidates or development programs for obesity, erectile dysfunction, cardiovascular diseases, pulmonary diseases, inflammatory diseases and dermatologic diseases.
More notable recent Palatin Technologies, Inc. (NYSEMKT:PTN) news were published by: Reuters.com which released: “BRIEF-Palatin Technologies, Inc. reports first quarter 2017 results” on November 15, 2016, also Prnewswire.com with their article: “Palatin Technologies Announces $9.25 Million Financing” published on August 01, 2016, Reuters.com published: “Exclusive: Female Viagra contender Palatin Technologies explores potential…” on November 02, 2016. More interesting news about Palatin Technologies, Inc. (NYSEMKT:PTN) were released by: Prnewswire.com and their article: “Palatin Technologies, Inc. Reports Fourth Quarter And Fiscal Year 2016 Results” published on September 20, 2016 as well as Prnewswire.com‘s news article titled: “Palatin Technologies Presents Bremelanotide Neurobiology and Treatment …” with publication date: September 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers